Recombinant Human MOG Protein (C-6His)

Name: Recombinant Human MOG Protein (C-6His)
Brand: Beta LifeScience
SKU: BL-0002NP
Availability: InStock

BL-0002NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: Other recombinant proteins, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Myelin Oligodendrocyte Glycoprotein is produced by our E.coli expression system and the target gene encoding Gly30-Gly154 is expressed with a 6His tag at the C-terminus.
Accession	Q16653
Synonym	Myelin-Oligodendrocyte Glycoprotein; MOG; MOG(1-125)
Gene Background	Myelin Oligodendrocyte Glycoprotein (MOG) is a transmembrane protein, which is expressed exclusively in the CNS. MOG contains a single Ig-domain exposed to the extracellular space that allows autoantibodies easy access. MOG protein has been identified as a crucial autoantigen for multiple sclerosis in humans. MOG is capable to produce a demyelinating multiple sclerosis-like diseases in experimental animals, namely experimental autoimmune encephalomyelitis (EAE), in rodents and monkeys.
Molecular Mass	15.2 KDa
Apmol Mass	16-18 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of 20mM HAc-NaAc, 150mM NaCl, pH 4.5.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Mediates homophilic cell-cell adhesion. Minor component of the myelin sheath. May be involved in completion and/or maintenance of the myelin sheath and in cell-cell communication.; (Microbial infection) Acts as a receptor for rubella virus.
Subcellular Location	[Isoform 1]: Cell membrane; Multi-pass membrane protein.; [Isoform 5]: Cell membrane; Multi-pass membrane protein.; [Isoform 2]: Cell membrane; Single-pass type I membrane protein.; [Isoform 3]: Cell membrane; Single-pass type I membrane protein.; [Isoform 4]: Cell membrane; Single-pass type I membrane protein.; [Isoform 6]: Cell membrane; Single-pass type I membrane protein.; [Isoform 7]: Cell membrane; Single-pass type I membrane protein.; [Isoform 8]: Cell membrane; Single-pass type I membrane protein.; [Isoform 9]: Cell membrane; Single-pass type I membrane protein.
Protein Families	Immunoglobulin superfamily, BTN/MOG family
Database References	HGNC: 7197 OMIM: 159465 KEGG: hsa:4340 STRING: 9606.ENSP00000366095 UniGene: Hs.141308
Associated Diseases	Narcolepsy 7 (NRCLP7)
Tissue Specificity	Found exclusively in the CNS, where it is localized on the surface of myelin and oligodendrocyte cytoplasmic membranes.

Gene Functions References

Anti-MOG positive patients may have manifestations that mimic neuromyelitis optica spectrum disorders but differ in their course and prognosis from anti-AQP4 positive NMOSD. PMID: 26498263
Molecular Dynamics (MD) simulations were used to explore the interactions of MOG35-55 at the receptor level. PMID: 27388119
Adoptive transfer of serum from anti-MOG Ab mice or of purified anti-MOG Ab 8.18C5 into naive 2D2 recipients triggered activation and expansion of T cells followed by severe and robust experimental autoimmune encephalomyelitis, suggesting that the mechanism of anti-MOG Ab-mediated opsonization of auto-antigen may indeed contribute to initiation and propagation of CNS demyelinating disease. PMID: 27022743
Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis. PMID: 28125740
Data show that aquaporin-4 (AQP4) and myelin-oligodendrocyte glycoprotein (MOG) autoantibodies double positive neuromyelitis optica spectrum disorder (NMOSD) patients had a multiphase disease course with a high annual relapse rate. PMID: 26920678
MOG antibody associated optic neuritis tends to involve the anterior optic pathway. PMID: 26163068
This study demonstrated that increased expression of mRNA of OLIG1 in ventral prefrontal white matter in major depressive disorder. PMID: 25930075
In patients with idiopathic optic neuritis, 27.6% (8/29) were positive for MOG antibodies. Three of the eight MOG-positive patients showed significantly high CSF levels of myelin basic protein. Five had optic pain and three had prodromal infection. PMID: 25838512
Immune modulation by a tolerogenic myelin oligodendrocyte glycoprotein (MOG)10-60 containing fusion protein in the marmoset experimental autoimmune encephalomyelitis model. PMID: 25393803
These data demonstrate a new role for myelin glycosylation in the control of immune homeostasis in the healthy human brain through the MOG-DC-SIGN homeostatic regulatory axis, which is comprised by inflammatory insults that affect glycosylation. PMID: 24935259
findings suggest that immune reactions toward MOG and in particular MOG-specific antibodies may play a functional role in multiple sclerosis PMID: 22494461
Patients with neuromyelitis optica spectrum disorders with MOG antibodies have distinct clinical features, fewer attacks, and better recovery than patients with AQP4 antibodies or patients seronegative for both antibodies. PMID: 24415568
Bipolar I disorder and schizophrenia share a number of common genetic risk loci and susceptibility genes including the genes coding for myelin oligodendrocytes glycoprotein (MOG). PMID: 23032943
We could show for the first time that a subset of aquaporin 4-IgG seronegative patients with neuromyelitis optica exhibit a MOG-IgG mediated immune response PMID: 22204662
This study provides valuable information about requirements of anti-myelin oligodendrocyte glycoprotein reactivity for being regarded as a prognostic biomarker in a subtype of MS. PMID: 22093619
The authors found that the human myelin oligodendrocyte glycoprotein (MOG) specifically bound to the E1 envelope glycoprotein of rubella virus, and an antibody against MOG could block rubella virus infection. PMID: 21880773
A missense mutation in myelin oligodendrocyte glycoprotein as a cause of familial narcolepsy with cataplexy. PMID: 21907016
The persistence or disappearance of antibodies to MOG may have prognostic relevance for acute childhood demyelination PMID: 21795651
Conformational structure of the MOG-derived peptide 101-108 in solution. PMID: 20549678
A mutated MOG peptide [MOG97-109] enables detection of MOG97-109-reactive T cells in multiple sclerosis patients bearing the HLA-DRB1*0401 allele. PMID: 21653833
Report provides evidence that the humoral immune response against MOG in children is specific for demyelinating inflammatory CNS disorders. PMID: 21177754
Persistence of MOG antibodies despite viral clearance in a high percentage of HIV-1 associated neurocognitive disorder (HAND) patients suggests ongoing neuroinflammation, possibly preventing recovery from HAND. PMID: 21083890
cell surface-expressed native myelin oligodendrocyte glycoprotein nor linear epitopes have a predictive or discriminative role during the preclinical disease phase for developing clinically isolated syndrome or multiple sclerosis later in life PMID: 20685767
The results of this study have observed that changes in splicing, but not expression levels, are associated with common genetic variation in the MOG gene PMID: 20800907
Our study provides first evidence that the MOG G511C (Val142Leu) polymorphism might be associated with structural changes in the total white matter volumes of OCD patients. PMID: 20452030
identification of T cell epitopes that are encephalitogenic and presented by B cells PMID: 11739534
The B cell and T cell epitopes have been identified in rat MOG-immunized marmosets, and these sequences are observed to map primarily onto accessible regions in the model, which may explain their ability to generate potent antibody responses. PMID: 11895369
A T cell reactivity pattern analysis of multiple sclerosis patients at the onset of relapse or progression shows that there is a highly immunogenic epitope for CD4+ T cells within the transmembrane/intracellular part of MOG comprising amino acids 146-154. PMID: 12077287
MOG-specific antibody is critical to the initiation of MOG-induced murine experimental autoimmune encephalomyelitis PMID: 12115610
polymorphisms do not provide evidence to support a significant role for MOG in multiple sclerosis susceptibility. PMID: 12149493
a substantial proportion of MOG-reactive T cells from some subjects have been activated in vivo without resulting in clinical disease PMID: 12482392
Human MOG is immunogenic and induces experimental autoimmune encephalomyelitis in C57BL/6 mice via an encephalitogenic B cell response to epitopes on human MOG protein that most likely cross-react with mouse determinants. PMID: 12817031
Demonstration of molecular mimicry between MOG and butyrophilin suggests that exposure to this common dietary antigen may influence the composition and function of the MOG-specific autoimmune repertoire during the course of multiple sclerosis. PMID: 14688379
No significant evidence for biased transmission of alleles at the (CA)n (chi2=2.430, 6 df, P=0.876) (TAAA)n (chi2=3.550, 5 df, P=0.616), C1334T (chi2=0.040, 1 df, P=0.841) and C10991T (chi2=0.154,polymorphisms in patients with schizophrenia was seen. PMID: 15660663
In human brain the splice variants of MOG appear at a late stage compared to the major isoform, coincidental with myelination and myelin maturation, unlike other myelin proteins. PMID: 16903876
pathogenic antibody response to native MOG in a subgroup of multiple sclerosis patients PMID: 17142321
This study represents the first evidence of alternative translation products from the MOG gene. To date, it is believed that alternative splicing of MOG is limited to primates. PMID: 17402967
results indicate that variation within the MOG gene is not an important independent determinant of multiple sclerosis -inherited risk in the Sardinian population PMID: 17509152
MOG may be a target of Hoxd1 PMID: 17554625
Our findings highlight myelin oligodendrocyte glycoprotein splicing as a factor that could be critical to the phenotypic expression of multiple sclerosis. PMID: 17573820
The associations observed in Japanese and French patients, the linkage studies and the present work speak in favor of the existence of a susceptibility gene for autism in the NF1 locus. PMID: 17897745
A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy. PMID: 17928868
although individuals with anti-myelin oligodendrocyte glycoprotein (MOG) antibodies have an increased risk of developing multiple sclerosis, this association may at least in part reflect cross-reactivity between MOG and Epstein-Barr nuclear antigen PMID: 18753473
genetic polymorphism is associated with autism in Sardinian children PMID: 19167444
B cell autoimmunity to this MOG is therefore most common in patients with a very early onset of MS PMID: 19687098

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.